---

Bill Lundberg

Chief Scientific Officer, CRISPR Therapeutics

Bill has extensive experience across all aspects and phases of drug development in both academic and industry settings. He was previously vice president and head of translational medicine at Alexion Pharmaceuticals, where he oversaw the progression of numerous compounds from early research to clinical proof-of-concept. Before that, Bill held senior positions at Taligen, Antisoma, Xanthus Wyeth and Genzyme.

---

Part of the Power List 2016

The Top 100

The nominations are in and after considerable debate and analysis from our judging panel, we present The Power List 2016 – our second foray into the Top 100 most influential people in the world of drug development and manufacture.

Go to The Power List 2016